When patients were grouped according to tumor response and changes in lymphocyte subpopulation counts were evaluated among those with different treatment outcomes (Figures 3B–G), we observed that both the counts of T cells (P =0.047), CD4+ T (P =0.020), and CD8+ T (P =0.030) in patients with PD showed progressive decline in T-cell counts. This evidence concerns the gene CD8A and neoplasm.